Tourmaline Bio Inc.

17.00
-0.32 (-1.85%)
At close: Apr 25, 2025, 2:22 PM
-1.85%
Bid 16.99
Market Cap 436.65M
Revenue (ttm) 40K
Net Income (ttm) -73.21M
EPS (ttm) -2.89
PE Ratio (ttm) -5.88
Forward PE -3.56
Analyst Buy
Ask 17.15
Volume 83,968
Avg. Volume (20D) 352,806
Open 17.16
Previous Close 17.32
Day's Range 16.70 - 17.61
52-Week Range 11.56 - 29.79
Beta 2.16

About TRML

Tourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune diseases. It develops medicines and therapies for the Atherosclerotic cardiovascular disease (ASCVD) and Thyroid Eye Disease (TED). The company was incorporated in 2021 and is based in New York, New York....

Industry Biotechnology
Sector Healthcare
IPO Date May 7, 2021
Employees 74
Stock Exchange NASDAQ
Ticker Symbol TRML
Full Company Profile

Analyst Forecast

According to 7 analyst ratings, the average rating for TRML stock is "Buy." The 12-month stock price forecast is $50, which is an increase of 194.12% from the latest price.

Stock Forecasts
1 month ago
+10.33%
Tourmaline Bio shares are trading higher on possib... Unlock content with Pro Subscription
1 month ago
+11.09%
Tourmaline Bio shares are trading higher after Wedbush initiated coverage on the stock with an Outperform rating and announced a price target of $42.